Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
01.09. | NEURIZON THERAPEUTICS LIMITED: Change of AGM Date | 3 | ASX | ||
NEURIZON THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
26.08. | NEURIZON THERAPEUTICS LIMITED: Neurizon to present Q4 updates to Shareholders | 5 | ASX | ||
26.08. | NEURIZON THERAPEUTICS LIMITED: Appendix 4G and Corporate Governance Statement | - | ASX | ||
26.08. | NEURIZON THERAPEUTICS LIMITED: Appendix 4E and 2025 Annual Report | - | ASX | ||
21.08. | Neurizon NUZ-001 OLE study demonstrates long-term safety, efficacy signals | 8 | The Market Herald Australia | ||
20.08. | NEURIZON THERAPEUTICS LIMITED: Notice of Shareholder Update Webinar | - | ASX | ||
20.08. | NEURIZON THERAPEUTICS LIMITED: NUZ-001 Shows Long-Term Safety and Efficacy Signals in OLE | - | ASX | ||
18.08. | Neurizon becomes second biotech hit with FDA delay for ALS candidate | 4 | FierceBiotech | ||
15.08. | FDA Extends Review Timeline for Neurizon's NUZ-001 Clinical Hold Response | 3 | Finance News Network | ||
15.08. | NEURIZON THERAPEUTICS LIMITED: FDA Review Timeline Extended for NUZ-001 IND Clinical Hold | 4 | ASX | ||
12.08. | NEURIZON THERAPEUTICS LIMITED: Neurizon Commences Manufacture of First Registration Batch | 2 | ASX | ||
05.08. | NEURIZON THERAPEUTICS LIMITED: AGM Date & Director Nominations Closing Date for AGM | 4 | ASX | ||
30.07. | ASX Health Quarterly Wrap: Neurizon turns up the dial on ALS drug progress | 2 | Stockhead | ||
30.07. | Neurizon inks $1.5M loan against R&D Tax Rebate | 2 | The Market Herald Australia | ||
30.07. | NEURIZON THERAPEUTICS LIMITED: Appendix 4C & Quarterly Update | - | ASX | ||
30.07. | NEURIZON THERAPEUTICS LIMITED: Neurizon Secures Loan Against 2025 R&D Tax Rebate | 1 | ASX | ||
27.07. | Neurizon closer to FDA clinical hold lift on ALS drug as it eyes crucial trial | 4 | Stockhead | ||
25.07. | NEURIZON THERAPEUTICS LIMITED: Neurizon Submits Clinical Hold Complete Response to FDA | 9 | ASX | ||
10.07. | Thursday's HotCopper trends: Mystery Trigg halt, Neurizon FDA feedback | July 10 | 2 | The Market Herald Australia | ||
10.07. | NEURIZON THERAPEUTICS LIMITED: Positive feedback from FDA on strategy to lift clinical hold | 2 | ASX |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
PFIZER | 20,380 | +0,12 % | Investor Woche: EZB hält Zinsen stabil, Fed vor Dilemma, Klarna mit starkem IPO, Novo Nordisk streicht stellen, Pfizer, Prismo Metals, Sotheby's, Larry Ellison, Elon Musk | EZB belässt Zinsen stabil. Die Fed dürfte kommende Woche trotz hartnäckiger Inflation wegen dem schwachen Arbeitsmarkt die Zinsen senken. Klarna mit starkem IPO, Sotheby's leidet am Kunstmarkt. Novo... ► Artikel lesen | |
NOVARTIS | 106,48 | +0,02 % | Novartis: Milliardenzukauf in den USA - satte Prämie | Der Schweizer Pharmariese Novartis plant die Übernahme des Biopharma-Unternehmens Tourmaline Bio. Der Kaufpreis liegt bei rund 1,4 Milliarden Dollar. Über eine indirekte Tochtergesellschaft bietet Novartis... ► Artikel lesen | |
GILEAD SCIENCES | 99,28 | +1,71 % | Telegram Trader AWSX: Startet diese Aktie jetzt durch? Neue Kooperation schürt Kurs-Fantasie | ||
ROCHE | 283,80 | +0,07 % | Research and Markets: Europe Liver Disease Therapeutic Market Analysis Report 2025-2033 Featuring Abbott, Astellas, BMS, Gilead Sciences, GSK, F. Hoffman-La Roche, Merck & Co., Novartis, Sanofi, Pfizer, Takeda - ResearchAndMarkets.com | The "Europe Liver Disease Therapeutic Market Forecast 2025" report has been added to ResearchAndMarkets.com's offering.
The Europe Liver Disease Therapeutic Market is expected to grow from US$... ► Artikel lesen | |
STADA ARZNEIMITTEL | - | - | Canson Capital Partners agiert als Federführender Finanzberater von Capvest bei der Akquisition von Stada und co-investiert über seinen Merchant Banking Arm | London (ots/PRNewswire) - STADA ist die sechste Private-Equity-Transaktion, bei der Canson als Finanzberater und Co-Investor auftrittCanson Capital Partners ("Canson") freut sich bekannt zu geben, dass... ► Artikel lesen | |
HALO COLLECTIVE | 0,010 | 0,00 % | Waters Corporation Buys Halo Labs | WASHINGTON (dpa-AFX) - Waters Corporation (WAT), an analytical instruments and software firm, said on Wednesday that it has acquired Halo Labs, a company focused on specialized imaging technologies... ► Artikel lesen | |
TEVA | 17,050 | +0,29 % | Teva Pharmaceutical Industries Ltd: Teva's Emrusolmin Granted U.S. FDA Fast Track Designation for Treatment of Multiple System Atrophy | Teva received Fast Track designation from the U.S. Food and Drug Administration for emrusolmin (TEV-56286), an investigational treatment for Multiple System Atrophy (MSA) in Phase 2 development.New... ► Artikel lesen | |
DIGICANN VENTURES | 0,004 | 0,00 % | Digicann Ventures Inc.: Digicann Ventures Provides Update Regarding Proposed RTO Transaction | / Not for distribution to U.S. news wire services or for dissemination in the United States / VANCOUVER, British Columbia, April 22, 2025 (GLOBE NEWSWIRE) -- Digicann Ventures Ltd. ("Digicann" or... ► Artikel lesen | |
EYEPOINT PHARMACEUTICALS | 11,435 | +0,44 % | EyePoint Pharmaceuticals, Inc.: EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | WATERTOWN, Mass., Aug. 18, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients... ► Artikel lesen | |
WPD PHARMACEUTICALS | 0,002 | 0,00 % | WPD Pharmaceuticals Inc (2): WPD Pharmaceuticals suspended by CSE | ||
IONIS PHARMACEUTICALS | 54,08 | +0,48 % | Ionis pharmaceuticals celebrates 10 years of adaptive event for rare diseases | ||
GREEN THUMB INDUSTRIES | 6,370 | +0,71 % | Green Thumb Industries Announces Brand Transactions with Agrify | CHICAGO and VANCOUVER, British Columbia, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Green Thumb Industries Inc. ("Green Thumb" or the "Company") (CSE: GTII) (OTCQX: GTBIF), a leading national cannabis consumer... ► Artikel lesen | |
SINOPHARM | 2,089 | +0,82 % | Aktie der Sinopharm Group heute am Aktienmarkt kaum gefragt: Kurs fällt (2,012 €) | Im Wertpapierhandel notiert das Wertpapier der Sinopharm Group derzeit leichter. Das Wertpapier notiert zur Stunde bei 2,01 Euro. Jahreschart der Sinopharm Group Ltd-Aktie, Stand 09.09.2025 Ein Minus... ► Artikel lesen | |
ASSEMBLY BIOSCIENCES | 18,550 | -0,27 % | Assembly Biosciences stock price target raised by Guggenheim to $39 on strong trial data | ||
INDIVA | 0,016 | -100,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 20.06.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 20.06.2025.Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 20.06.2025.ISIN NameCA45580J1012 INDIVA... ► Artikel lesen |